

Peter B Gilbert

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3670716/peter-b-gilbert-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162
papers

14,689
citations

44
h-index

120
g-index

173
ext. papers

20,281
ext. citations

10.8
avg, IF

6.44
L-index

#	Paper	IF	Citations
162	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021 , 384, 403-416	59.2	3691
161	Immune-correlates analysis of an HIV-1 vaccine efficacy trial. <i>New England Journal of Medicine</i> , 2012 , 366, 1275-86	59.2	1400
160	Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. <i>Lancet, The</i> , 2008 , 372, 1881-1893	40	1343
159	Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. <i>Journal of Virology</i> , 2005 , 79, 10108-25	6.6	939
158	Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. <i>Journal of Virology</i> , 2010 , 84, 1439-52	6.6	514
157	Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. <i>New England Journal of Medicine</i> , 2013 , 369, 2083-92	59.2	434
156	Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. <i>New England Journal of Medicine</i> , 2018 , 379, 327-340	59.2	368
155	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. <i>Nature</i> , 2012 , 490, 417-20	50.4	342
154	Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. <i>Science Translational Medicine</i> , 2014 , 6, 228ra39	17.5	336
153	Evidence for antibody as a protective correlate for COVID-19 vaccines. <i>Vaccine</i> , 2021 , 39, 4423-4428	4.1	277
152	Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. <i>Journal of Infectious Diseases</i> , 2012 , 206, 431-41	7	229
151	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. <i>New England Journal of Medicine</i> , 2015 , 373, 2025-2037	59.2	225
150	Nomenclature for immune correlates of protection after vaccination. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1615-7	11.6	216
149	Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. <i>PLoS ONE</i> , 2014 , 9, e87572	3.7	209
148	Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. <i>PLoS ONE</i> , 2013 , 8, e75665	3.7	189
147	Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. <i>Nature Medicine</i> , 2011 , 17, 366-71	50.5	186
146	COMPASS identifies T-cell subsets correlated with clinical outcomes. <i>Nature Biotechnology</i> , 2015 , 33, 610-6	44.5	165

145	Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. <i>Lancet Infectious Diseases, The</i> , 2012 , 12, 531-7	25.5	162
144	Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). <i>Journal of Infectious Diseases</i> , 2012 , 206, 258-66	7	161
143	A framework for assessing immunological correlates of protection in vaccine trials. <i>Journal of Infectious Diseases</i> , 2007 , 196, 1304-12	7	161
142	The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 1444-57 ^{1.6}	17.6	159
141	Immune correlates of vaccine protection against HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015 , 7, 310rv7	17.5	142
140	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2022 , 375, 43-50	33.3	116
139	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021 , 385, 1774-1785	59.2	105
138	Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. <i>Journal of Infectious Diseases</i> , 2010 , 202, 595-605	7	101
137	Prospects for a safe COVID-19 vaccine. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	99
136	Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. <i>Vaccine</i> , 2006 , 24, 6893-904	4.1	86
135	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <i>Journal of Clinical Investigation</i> , 2014 , 124, 3879-90	15.9	86
134	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2021 , eab3435	33.3	84
133	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. <i>Lancet Infectious Diseases, The</i> , 2014 , 14, 388-96	25.5	80
132	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021 , 384, 1003-1014	59.2	77
131	Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. <i>Journal of Infectious Diseases</i> , 2011 , 203, 969-75	7	69
130	Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. <i>Journal of Infectious Diseases</i> , 2014 , 210, 1573-81	7	68
129	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV,the</i> , 2018 , 5, e366-e378	7.8	62
128	chnppt: threshold regression model estimation and inference. <i>BMC Bioinformatics</i> , 2017 , 18, 454	3.6	56

127	Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. <i>Journal of Infectious Diseases</i> , 2013 , 208, 1231-9	7	55
126	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4838-4849	15.9	55
125	Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. <i>Journal of Infectious Diseases</i> , 2018 , 217, 742-753	7	54
124	Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. <i>Journal of Immunological Methods</i> , 2012 , 375, 57-67 ^{2.5}		51
123	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017 , 9,	0.7	50
122	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , 2021 , 174, 221-228	8	47
121	Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial 2021 ,		46
120	Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. <i>PLoS Computational Biology</i> , 2015 , 11, e1003973	5	44
119	Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. <i>Journal of Virology</i> , 2014 , 88, 8242-55	6.6	44
118	Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017 , 215, 1376-1385	7	43
117	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. <i>Cell Host and Microbe</i> , 2019 , 26, 336-346.e3	23.4	43
116	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. <i>PLoS ONE</i> , 2017 , 12, e0180720	3.7	42
115	Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. <i>EBioMedicine</i> , 2014 , 1, 37-45	8.8	40
114	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015 , 7, 296ra112	17.5	38
113	Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation. <i>Journal of Clinical Epidemiology</i> , 2001 , 54, 68-85	5.7	36
112	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. <i>New England Journal of Medicine</i> , 2021 , 384, 1089-1100	59.2	36
111	Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. <i>MAbs</i> , 2017 , 9, 792-800	6.6	33
110	Simultaneous inferences on the contrast of two hazard functions with censored observations. <i>Biometrics</i> , 2002 , 58, 773-80	1.8	33

109	Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E8378-E8387	11.5	32
108	Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development. <i>Statistics in Biopharmaceutical Research</i> , 2009 , 1, 81-91	1.2	31
107	HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. <i>PLoS Pathogens</i> , 2013 , 9, e1003404	7.6	30
106	Covariability of selected amino acid positions for HIV type 1 subtypes C and B. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 1016-30	1.6	30
105	Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials. <i>PLoS ONE</i> , 2016 , 11, e0147812	3.7	30
104	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. <i>Nature Medicine</i> , 2015 , 21, 1139-41	50.5	29
103	DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 T-Cell Responses by Interleukin-12 Plasmid DNA. <i>Vaccine Journal</i> , 2017 , 24,		24
102	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	24
101	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019 , 6, e737-e749	7.8	23
100	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. <i>PLoS ONE</i> , 2015 , 10, e0137666	3.7	22
99	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. <i>Journal of Infectious Diseases</i> , 2018 , 217, 1280-1288	7	20
98	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. <i>PLoS ONE</i> , 2017 , 12, e0179597	3.7	20
97	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017 , 12, e0185959	3.7	20
96	Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl. <i>International Journal of Biostatistics</i> , 2011 , 7, Article 36	1.3	18
95	Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts. <i>Statistics in Medicine</i> , 2010 , 29, 1061-71	2.3	18
94	Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. <i>Nature Communications</i> , 2019 , 10, 863	17.4	17
93	Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon- β secretion with increased HIV-1 infection risk: a cohort-based modeling study. <i>PLoS ONE</i> , 2014 , 9, e108631	3.7	17
92	Genome scanning tests for comparing amino acid sequences between groups. <i>Biometrics</i> , 2008 , 64, 198-207	10.7	17

91	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. <i>Journal of Virology</i> , 2019 , 93,	6.6	16
90	Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. <i>Journal of AIDS & Clinical Research</i> , 2015 , 6,	1	15
89	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015 , 10, e0136626	3.7	15
88	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020 , 17, e1003038	11.6	14
87	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. <i>Human Vaccines and Immunotherapeutics</i> , 2018 , 14, 2116-2127	4.4	14
86	Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2015 , 64, 49-73	1.5	14
85	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , 2019 , 10, 2741	8.4	14
84	Nonparametric variable importance assessment using machine learning techniques. <i>Biometrics</i> , 2021 , 77, 9-22	1.8	14
83	Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. <i>Lancet HIV, the</i> , 2019 , 6, e475-e482	7.8	13
82	Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. <i>PLoS Computational Biology</i> , 2019 , 15, e1006952	5	13
81	Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study. <i>Scientific Reports</i> , 2018 , 8, 6066	4.9	13
80	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2018 , 34, 645-656	1.6	13
79	Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials 2020 ,		13
78	HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy. <i>BMC Infectious Diseases</i> , 2019 , 19, 453	4	11
77	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. <i>PLoS ONE</i> , 2017 , 12, e0176428	3.7	11
76	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. <i>Current Opinion in Virology</i> , 2016 , 17, 57-65	7.5	11
75	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. <i>PLoS ONE</i> , 2016 , 11, e0161753	3.7	11
74	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020 , 10, 2093	4.9	10

73	Improved estimation of the cumulative incidence of rare outcomes. <i>Statistics in Medicine</i> , 2018 , 37, 280-293	2.9	10
72	Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition. <i>Journal of Causal Inference</i> , 2015 , 3, 157-175	1.9	10
71	FCGR2C Polymorphisms Associated with HIV-1 Vaccine Protection Are Linked to Altered Gene Expression of Fc-γ Receptors in Human B Cells. <i>PLoS ONE</i> , 2016 , 11, e0152425	3.7	10
70	Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic Helical Structure. <i>PLoS ONE</i> , 2017 , 12, e0170530	3.7	10
69	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020 , 15, e0226803	3.7	10
68	Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy. <i>Epidemiologic Methods</i> , 2016 , 5, 93-112	2.2	10
67	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation.. <i>Scientific Reports</i> , 2021 , 11, 23921	4.9	10
66	Estimation of the optimal surrogate based on a randomized trial. <i>Biometrics</i> , 2018 , 74, 1271-1281	1.8	9
65	Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1540-1544	11.4	9
64	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , 2021 , 174, 1118-1125	8	9
63	Estimating and Testing Vaccine Sieve Effects Using Machine Learning. <i>Journal of the American Statistical Association</i> , 2019 , 114, 1038-1049	2.8	8
62	Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. <i>Vaccine Journal</i> , 2014 , 21, 1589-99		8
61	Antigenic competition in CD4 T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	8
60	Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection. <i>PLoS Pathogens</i> , 2021 , 17, e1009406	7.6	7
59	Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1927-1939	11.6	7
58	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , 2021 , 64, 103203	8.8	7
57	Statistical Learning Methods to Determine Immune Correlates of Herpes Zoster in Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2018 , 218, S99-S101	7	7
56	A government-led effort to identify correlates of protection for COVID-19 vaccines. <i>Nature Medicine</i> , 2021 , 27, 1493-1494	50.5	7

55	Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. <i>Vaccine</i> , 2017 , 35, 1184-1193	4.1	6
54	Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment. <i>Viruses</i> , 2019 , 11,	6.2	6
53	Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials. <i>Journal of the American Statistical Association</i> , 2013 , 108,	2.8	6
52	Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 87, 671-679	3.1	6
51	Power/sample size calculations for assessing correlates of risk in clinical efficacy trials. <i>Statistics in Medicine</i> , 2016 , 35, 3745-59	2.3	6
50	Inference on treatment effect modification by biomarker response in a three-phase sampling design. <i>Biostatistics</i> , 2020 , 21, 545-560	3.7	6
49	Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial. <i>Journal of Virology</i> , 2019 , 93,	6.6	5
48	Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus. <i>Vaccine</i> , 2020 , 38, 3531-3536	4.1	5
47	A regularized estimation approach for case-cohort periodic follow-up studies with an application to HIV vaccine trials. <i>Biometrical Journal</i> , 2020 , 62, 1176-1191	1.5	5
46	Modeling HIV vaccine trials of the future. <i>Current Opinion in HIV and AIDS</i> , 2016 , 11, 620-627	4.2	5
45	Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials. <i>Statistics in Medicine</i> , 2019 , 38, 4503-4518	2.3	5
44	Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trials. <i>Statistics in Medicine</i> , 2014 , 33, 901-17	2.3	5
43	Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials. <i>Biometrics</i> , 2020 ,	1.8	5
42	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. <i>PLoS Pathogens</i> , 2021 , 17, e1009363	7.6	5
41	Mark-specific hazard ratio model with missing multivariate marks. <i>Lifetime Data Analysis</i> , 2016 , 22, 606-253		5
40	SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials. <i>Bioinformatics</i> , 2017 , 33, 2386-2388	7.2	4
39	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. <i>PLoS ONE</i> , 2020 , 15, e0234236	3.7	4
38	A joint model for mixed and truncated longitudinal data and survival data, with application to HIV vaccine studies. <i>Biostatistics</i> , 2018 , 19, 374-390	3.7	4

37	Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019 , 101, 164-179	3.2	4
36	Vaccines that prevent SARS-CoV-2 transmission may prevent or dampen a spring wave of COVID-19 cases and deaths in 2021		4
35	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. <i>Npj Vaccines</i> , 2021 , 6, 56	9.5	4
34	Causal Isotonic Regression. <i>Journal of the Royal Statistical Society Series B: Statistical Methodology</i> , 2020 , 82, 719-747	3.9	3
33	Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. <i>MSphere</i> , 2020 , 5,	5	3
32	Calibration weighted estimation of semiparametric transformation models for two-phase sampling. <i>Statistics in Medicine</i> , 2015 , 34, 1695-707	2.3	3
31	RV144 HIV-1 vaccination impacts post-infection antibody responses. <i>PLoS Pathogens</i> , 2020 , 16, e1009101	1.6	3
30	Search continues for a CMV vaccine for transplant recipients. <i>Lancet Haematology</i> , 2016 , 3, e58-9	14.6	3
29	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. <i>Viruses</i> , 2021 , 13,	6.2	3
28	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020-March 2021) Using a Statistical Learning Strategy.. <i>Viruses</i> , 2021 , 14,	6.2	3
27	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020 , 17, e1003117	11.6	2
26	A general framework for inference on algorithm-agnostic variable importance. <i>Journal of the American Statistical Association</i> , 1-38	2.8	2
25	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (2020/01 - 2021/03) Using a Statistical Learning Strategy 2021 ,		2
24	Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	2
23	Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs. <i>Statistical Communications in Infectious Diseases</i> , 2019 , 11,	0.7	2
22	Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 83, 434-439	3.1	1
21	Generating Survival Times Using Cox Proportional Hazards Models with Cyclic and Piecewise Time-Varying Covariates. <i>Statistics in Biosciences</i> , 2020 , 12, 1-16	1.5	1
20	Use of placebos in Phase 1 preventive HIV vaccine clinical trials. <i>Vaccine</i> , 2015 , 33, 749-52	4.1	1

19	Innovative vaccine approaches-a Keystone Symposia report.. <i>Annals of the New York Academy of Sciences</i> , 2022 ,	6.5	1
18	Evaluating the Efficacy of COVID-19 Vaccines		1
17	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. <i>Virus Evolution</i> , 2021 , 7, veab057	3.7	1
16	Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation 2021 ,		1
15	Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention.. <i>PLoS Computational Biology</i> , 2022 , 18, e1010003	5	1
14	Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. <i>Human Immunology</i> , 2021 , 83, 53-53	2.3	0
13	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A25-A26	1.6	
12	Reply to Dunning. <i>Journal of Infectious Diseases</i> , 2015 , 212, 1521-3	7	
11	Rejoinder to A Note on Two-Sample Tests for Comparing Intra-Individual Genetic Sequence Diversity Between Populations <i>Biometrics</i> , 2012 , 68, 1326-1326	1.8	
10	Assessing trends in vaccine efficacy by pathogen genetic distance 2020 , 161, 164-175		
9	Methods for comparing durability of immune responses between vaccine regimens in early-phase trials. <i>Statistical Methods in Medical Research</i> , 2020 , 29, 78-93	2.3	
8	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials 2020 , 16, e1007626		
7	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials 2020 , 16, e1007626		
6	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials 2020 , 16, e1007626		
5	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials 2020 , 16, e1007626		
4	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America 2020 , 15, e0234236		
3	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America 2020 , 15, e0234236		
2	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America 2020 , 15, e0234236		

- 1 Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America **2020**, 15, e0234236